throbber
Trademark Trial and Appeal Board Electronic Filing System. http://estta.uspto.gov
`ESTTA624336
`ESTTA Tracking number:
`08/29/2014
`
`Filing date:
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD
`Petition for Cancellation
`
`Notice is hereby given that the following party requests to cancel indicated registration.
`Petitioner Information
`
`Name
`Entity
`Address
`
`BBK Holdings, LLC
`Limited Liability Company
`117 Kendrick Street Suite 600
`Needham, MA 02494
`UNITED STATES
`
`Citizenship
`
`Massachusetts
`
`Attorney informa-
`tion
`
`Sheri S. Mason
`Morse, Barnes-Brown & Pendleton, P.C>
`230 Third Avenue, 4th Floor CityPoint
`Waltham, MA 02451
`UNITED STATES
`ttab@mbbp.com, tdunn@mbbp.com, smason@mbbp.com Phone:781 622 5930
`Registration Subject to Cancellation
`
`Registration No
`Registrant
`
`4133304
`Epernicus, LLC
`35 Highland Circle, Suite 300
`Needham, MA 02494
`UNITED STATES
`Goods/Services Subject to Cancellation
`
`Registration date
`
`04/24/2012
`
`Class 042. First Use: 2011/04/01 First Use In Commerce: 2011/04/01
`All goods and services in the class are cancelled, namely: Computer services, namely, providing on-
`line communities for members of medicalresearch project teams to share information, collaborate,
`participate in discussions, receive information through emailand search for relevant content; Software
`as a service (SAAS) services, namely,hosting software for use by others for managing and exchan-
`ging medical information, content and documents; Providing a resource website featuring searchable
`databases and document libraries featuringinformation in the field of medical research in the field of
`clinical trials
`Class 044. First Use: 2011/04/01 First Use In Commerce: 2011/04/01
`All goods and services in the class are cancelled, namely: Providing a resource website featuring
`searchable databases and document libraries featuring information in the field of medicine
`
`Grounds for Cancellation
`
`Genericness
`
`Related Proceed-
`ings
`
`Trademark Act section 23
`
`TCN Technologies, LLC and BBK Holdings, LLC v. Epernicus, LLC, d/b/a Trial-
`Networks and DrugDev, Inc., Massachusetts District Court, Civil Action No.
`1:14-cv-12057-RBC
`
`Attachments
`
`Petition to Cancel - Generic (BBKHTM-ADV003) (M0679773).PDF(113574
`
`

`
`bytes )
`Part 1 (M0679786).PDF(670068 bytes )
`Part 2 (M0679787).PDF(1124698 bytes )
`Part 3 (M0679788).PDF(1366287 bytes )
`Part 4 (M0679789).PDF(3351609 bytes )
`Part 5 (M0679033).PDF(4933164 bytes )
`
`Certificate of Service
`
`The undersigned hereby certifies that a copy of this paper has been served upon all parties, at their address
`record by First Class Mail on this date.
`
`Signature
`Name
`Date
`
`/Sheri S. Mason/
`Sheri S. Mason
`08/29/2014
`
`

`
`
`
`
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD
`
`
`____________________________________
`
`
`
`
`
`)
`TCN Technologies, LLC,
`
`
`)
`
`
`
`
`
`)
`Petitioner,
`
`
`
`)
`
`
`
`
`
`)
`
`
`v.
`
`
`)
`)
`)
`
`
`
`Epernicus, LLC
`)
`
`
`
`
`
`)
`
`
`
`Registrant.
`____________________________________)
`
`
`In re Reg No.
`
`4,133,304
`
`
`
`Mark:
`
`Filing Date:
`
`Reg. Date:
`
`
`Cancellation No.:
`
`
`
`“TrialNetworks”
`
`January 18, 2011
`
`April 24, 2012
`
`_______________
`
`
`PETITION FOR CANCELLATION
`
`
`
`TCN Technologies, LLC (“Petitioner”) believes that it is damaged by the continued
`
`registration of “TrialNetworks”, shown in U.S. Registration No. 4,133,304, (hereinafter
`
`“Registration”), registered on April 24, 2012 by Epernicus, LLC, d/b/a “TrialNetworks”
`
`(“Registrant”). Petitioner hereby petitions to cancel the Registration pursuant to Section 14 of
`
`the Lanham Act, 15 U.S.C. §1064.
`
`As grounds for the cancellation of the Registration are as follows:
`
`I.
`
`INTRODUCTION
`
`1.
`
`Petitioner is a limited liability company organized and existing under the laws of
`
`the Commonwealth of Massachusetts, with a business address of 117 Kendrick Street Suite 600,
`
`Needham, Massachusetts, 02494.
`
`2.
`
`On information and belief, Registrant is a limited liability company organized and
`
`existing under the laws of Delaware and has a business address of 383 Elliot Street, Suite G,
`
`Newton, Massachusetts, 02464.
`
`
`
`{M0677433.1 }
`
`1
`
`

`
`
`
`3.
`
`Petitioner’s mission is to accelerate time-to-market for new and improved
`
`medicines and treatments by streamlining the clinical trial enrollment process through innovative
`
`strategies, programs, and technologies.
`
`4.
`
`Petitioner is a well-known provider of various technologies and related services in
`
`the field of clinical trials, including but not limited to TRIALCENTRALNET, a non-
`
`downloadable web application for management of multiple elements of clinical research study
`
`operations inclusive of patient recruitment and retention programs, tools, and processes; a web-
`
`based software application for identifying, recruiting and managing the participation of patients
`
`in clinical trials; and software as a service (SAAS) services featuring software for identifying,
`
`recruiting and managing the participation of patients in clinical trials, managing and monitoring
`
`activities and performance of various members of clinical study teams, and providing metrics
`
`and reporting on each of these activities. Petitioner is a holding company and the sole owner of
`
`TCN Technologies, LLC. Petitioner also is the parent company of BBK Worldwide, LLC, a full-
`
`service marketing consultancy specializing in patient recruitment and engagement in the
`
`biopharmaceutical and medical device industry. BBK Worldwide often incorporates
`
`TRIALCENTRALNET software in its service offerings to its customers. BBK Worldwide was
`
`founded in 1983 as BB&K Communications, Inc.Petitioner provides a clinical trial optimization
`
`and management solution on its website, www.trialcentralnet.com.
`
`5.
`
`Petitioner has offered clinical trial goods and services in interstate commerce
`
`since at least as early as 2003.
`
`II.
`
`THE REGISTRATION
`
`
`
`{M0677433.1 }
`
`2
`
`

`
`
`
`6.
`
`On January 18, 2011, Registrant filed an application to register “TrialNetworks”
`
`(as a standard character mark) on the Principal Register under Section 1(b) of the Lanham Act,
`
`15 U.S.C. § 1051(a).
`
`7.
`
`On March 2, 2012, the Registrant amended its application to register
`
`“TrialNetworks” on the Supplemental Register.
`
`8.
`
`On March 2, 2012, Registrant filed an Allegation of Use, alleging the date of first
`
`use for “TrialNetworks” is April 1, 2011.
`
`9.
`
`On April 24, 2012, “TrialNetworks” was registered for use in connection with
`
`“Computer services, namely, providing on-line communities for members of medical research
`
`project teams to share information, collaborate, participate in discussions, receive information
`
`through email and search for relevant content; Software as a service (SAAS) services, namely,
`
`hosting software for use by others for managing and exchanging medical information, content
`
`and documents; Providing a resource website featuring searchable databases and document
`
`libraries featuring information in the field of medical research in the field of clinical trials” in
`
`International Class 42 and “Providing a resource website featuring searchable databases and
`
`document libraries featuring information in the field of medicine” in International Class 44 (the
`
`“Services”), see Exhibit A.
`
`III. TRIALNETWORKS IS GENERIC
`
`10.
`
`“Trial” is defined as “a tryout or experiment to test quality, value, or usefulness.”
`
`In the medical industry, a “trial” is interpreted to mean “clinical trial,” see Exhibit B.
`
`11.
`
`Registrant’s Services are used “in the field of medical research in the field of
`
`clinical trials” (emphasis added), see Exhibit C.
`
`
`
`{M0677433.1 }
`
`3
`
`

`
`
`
`12.
`
` “Network” is defined as “a group of people or organizations that are closely
`
`connected and that work with each other,” see Exhibit D.
`
`13.
`
`“Clinical trial network” (or “trial network”) is defined as a “formalized
`
`consortium, collective, cooperative or collaborative research group established for the purpose of
`
`facilitating the conduct of clinical trial research,” see Exhibit E.
`
`14.
`
`Defendant uses the term “trial networks” is used generically on Registrant’s
`
`website, which is or has been made available by Registrant as an example of the clinical trial
`
`networks functionality of its “Trial Network” services, see Exhibit F.
`
`15.
`
`In the medical industry, a “network” is a generic term for members of medical
`
`research project teams, see Exhibit G.
`
`16.
`
`Registrant’s Services are for “members of medical research project teams” and
`
`are used “for managing and exchanging medical information, content and documents,” see
`
`Exhibit H.
`
`17.
`
`The terms “trial” and “network” are widely used in combination with each other
`
`as a generic phrase for a group of medical researchers or other healthcare professionals in a
`
`network intended to provide research for clinical trials, see Exhibit I.
`
`18.
`
`“Trial” and “network” are also widely used in combination with each other to
`
`refer to research conducted in industries (including the technology industry) by a group of
`
`researchers or other professionals, see Exhibit J.
`
`19.
`
`“TrialNetworks” combines the two generic terms “trial” and “network” into a
`
`compound work, “TrialNetworks.”
`
`
`
`{M0677433.1 }
`
`4
`
`

`
`
`
`20.
`
`Taken as a whole, “TrialNetworks” is a generic phrase for a group of medical
`
`researchers or other professionals in a network proving research for clinical trials, or a “trial
`
`network.”
`
`21.
`
`Registrant’s Services provide a network of medical researchers or other healthcare
`
`professionals conducting clinical trial research the ability: (i) to share information, collaborate,
`
`participate in discussions, receive information for a clinical trial for research purposes; (ii) to
`
`manage and exchange information, content and documents; and (iii) to conduct research
`
`information in the medical industry.
`
`22.
`
`The term “trial networks” is generic in that the primary meaning of the term to the
`
`relevant public is the same as the name for a network of medical researchers or other healthcare
`
`professionals conducting clinical trial research.
`
`23.
`
`24.
`
`“TrialNetworks” is generic for Registrant’s Services.
`
`Because “TrialNetworks” is generic, Petitioner is damaged by the continued
`
`registration of the “TrialNetworks.”
`
`WHEREFORE, Petitioner respectfully requests that this Petition to Cancel be sustained
`
`and the Registration be canceled.
`
`Respectfully submitted by:
`
`
`
`
`
`
`
`
`
`
`
`
`TCN Technologies, LLC
`
`By its attorneys
`
`MORSE, BARNES-BROWN & PENDLETON,
`P.C.
`
`By:
`
`
`/s/ Sheri S. Mason___________________________
`Sheri S. Mason, Esq.
`
`{M0677433.1 }
`
`5
`
`Date: August 29, 2014
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Thomas Dunn, Esq.
`230 Third Avenue, 4th Floor
`Waltham, MA 02451
`Tel:
`(781) 622-5930
`Fax:
`(781) 622 5933
`Email: ttab@mbbp.com
`
`{M0677433.1 }
`
`6
`
`

`
`
`
`CERTIFICATE OF SERVICE
`
`
`I, Sheri S. Mason, certify that a copy of the foregoing Petition to Cancel was served on:
`
`
`Robert D. Carroll, Esq.
`Goodwin Procter LLP
`Exchange Place, 53 State Street
`Boston, MA 02109
`
`by placing same with the U.S. Postal Service, Priority Mail, postage pre-paid, this 29th day of
`August, 2014.
`
`
`
`/s/ Sheri S. Mason_____________________
`Sheri S. Mason
`TCN Technologies, LLC
`
`{M0677433.1 }
`
`7
`
`
`
`
`
`
`
`

`
`EXHIBIT A
`
`

`
`qgguitkb%Im'tetI £tatn2s< ilfiatent ant: fltrahemark ®ffice
`
`TRIALNETWORKS
`
`EPERNICUS, LLC (DELAWARE LIMITED LIABILITY COMPANY)
`35 HIGHLAND CIRCLE, SUITE 300
`NEEDHAM, MA 02494
`
`FOR: COMPUTER SERVICES, NAMELY, PROVIDING ON-LINE COMMITNITIES FOR
`MEMBERS OF MEDICAL RESEARCH PROJECT TEAMS TO SHARE INFORMATION,
`COLLABORATE, PARTICIPATE IN DISCUSSIONS, RECEIVE INFORMATION THROUGH
`EMAIL AND SEARCH FOR RELEVANT CONTENT; SOFTWARE AS A SERVICE (SAAS)
`SERVICES, NAMELY, HOSTING SOFTWARE FOR USE BY OTHERS FOR MANAGING
`AND EXCHANGING MEDICAL INFORMATION, CONTENT AND DOCUMENTS;
`PROVIDING A RESOURCE WEBSITE FEATURING SEARCHABLE DATABASES AND
`DOCUMENT LIBRARIES FEATURING INFORMATION IN THE FIELD OF MEDICAL RE-
`SEARCII IN THE FIELD OF CLINICAL TRIALS, IN CLASS 42 (US CLS. 100 AND 101),
`
`FIRST USE 4-I-2011; IN COMMERCE 4-I-2011.
`
`FOR: PROVIDING A RESOURCE WEBSITE FEATURING SEARCHABLE DATABASES AND
`DOCUMENT LIBRARIES FEATURING INFORMATION IN THE FIELD OF MEDICINE, IN
`CLASS 44 (US. CLS. IOOAND 101).
`
`FIRST USE 4-1-2011; IN COMMERCE 4-1-2011.
`
`THE MARK CONSISTS OF STANDARD CHARACTERS WITHOUT CLAIM TO ANY PAR-
`TICULAR FONT, STYLE, SIZE, OR COLOR.
`
`SER. NO. 85—220,267, FILED P.R I-18-201 I; AM, S.R 3-2-2012.
`
`MARIA-VICTORIA SUAREZ, EXAMINING ATTORNEY
`
`Reg. No. 4,133,304
`
`Registered Apr. 24, 2012
`
`Int. Cls.: 42 and 44
`
`SERVICE MARK
`
`SUPPLEMENTAL REGISTER
`
`
`
`))irecluruI'1Im United Slums Palcm und 'J‘uuIe1nurk ()IT1ue
`
`

`
`EXHIBIT B
`
`

`
`Trial — Definition and More from the Free Merriam-Webster Dictionary
`
`Page 2 of 3
`
`Synonyms
`cross, crucible, fire, gauntlet (also gantiet), ordeal,
`baptism of fire
`; more
`
`atrial arijecriive
`: relating to or used in a test that is done for a period of
`time to see if something is worth buying, using, etc,
`
`H11! iffietirrition of ‘l’R'iifi.i,,,
`
`1 : of, relating to, or used in a trial
`2 : made or done as a test or experiment
`
`3 : used or tried out in a test or experiment
`
`:2? See trial defined for English-language learners >>
`
`iixarrspleez of Wéifiafim
`
`trial use of the product
`
`If you choose to use the software beyond the 30-day free
`trial period, you are required to pay for it.
`
`airs: Krsown £,¥:;¢2 of Weigltt,
`
`1555
`
`ileizzmrl to Tséifmi
`
`‘:3ynon\;m§l
`developmental, pilot, experimental
`[-6 ii‘(lOi‘(.-7
`
`flhymes with ”¥”i'«tIfiiL
`
`dial, file, isle, pile, smile, spiie, stile, style, tile, while, wile
`
`tri-al
`
`norm \‘tr'i(v-a)l\
`
`(Medr‘m!€?im’aria:'y}
`
`Medical tisefiniriryn C}? W121!/Si,
`
`1
`
`: a tryout or experiment to test quality, value, or
`usefulness—see CLINICAL 'l"R;AL
`2 : one of a number of repetitions of an experiment
`
`
`
`Q
`
`trial mean
`
`(Crmcise Eneyciopeciia)
`
`In law, a judicial examination of issues of fact or law for the
`purpose of determining the rights of the parties involved.
`Attorneys for the plaintiff and the defendant make opening
`statements to a judge or jury, then the attorney for the
`plaintiff makes his case by calling witnesses, whom the
`defense attorney may cross—examine. Unless the case is then
`dismissed for lack of sufficient evidence, the defense attorney
`next takes a turn calling witnesses, whom the plaintiff's
`attorney cross—exam|nes. Both sides make closing arguments.
`In a trial before a jury, the judge instructs the jury on the
`applicable laws, and the jury retires to reach a verdict, If the
`defendant is found guilty, the judge then hands down a
`sentence.
`
`imzzarn More Mzout Wtmt
`
`fiffhesaurusz All synonyms and antonyms for "trial"
`Qfespanish Central Translation: "trial" in Spanish
`§§,13ritannica.com: Encyclopedia article about "trial"
`
`Browse
`
`http://wwwmerriarn-Webster.com/dictionary/trial
`
`8/27/2014
`
`

`
`EXHIBIT C
`
`

`
`étatnzz of amen,”
`r®xx'\t\ZIJIlléiniteh Qtatnzszé ilfiatent anti Ulrahemark ®ff1'z2
`
`TRIALNETWORKS
`
`EPERNTCUS, LLC (DELAWARE LIMITED LIABILITY COMPANY)
`35 HIGHLAND CIRCLE, SUITE 300
`NEEDHAM, MA 02494
`
`FOR: COMPUTER SERVICES, NAMELY, PROVIDING ON—I.INE COMMUNITIES FOR
`MEMBERS OF MEDICAL RESEARCH PROJECT TEAMS TO SHARE INFORMATION,
`COLLABORATE, PARTICIPATE IN DISCUSSIONS, RECEIVE INFORMATION THROUGH
`EMAIL AND SEARCH FOR RELEVANT CONTENT; SOFTWARE AS A SERVICE (SAAS)
`SERVICES, NAMELY, HOSTING SOFTWARE FOR USE BY OTHERS FOR MANAGING
`AND EXCHANGING MEDICAL INFORMATION, CONTENT AND DOCUMENTS;
`PROVIDING’ A RESOURCE WEBSITE FEATURING SEARCHABLE DATABASES AND
`DOCUMENT LIBRARIES FEATURING INFORMATIONOF MEDICAL RE-
`
`S__E_ARCII IN THE FIELD OF CLINICAL TRIALS, IN CLASS 42 (U.S. CLS. 100 AND 101).
`
`FIRST USE 4-1-2011; IN COMMERCE 4-1-2011.
`
`FOR: PROVIDING A RESOURCE WEBSITE FEATURING SEA RCIIABLE DATABASES AND
`DOCUMENT LIBRARIES FEATURING INFOR\/IATION IN THE FIELD OF MEDICINE, IN
`CLASS 44 (US. CLS. I00 AND 101).
`
`FIRST USE 4—I—20I I; IN COMMERCE 4-]-2011.
`
`THE MARK CONSISTS OF STANDARD CHARACTERS WITHOUT CLAIM TO ANY PAR-
`TICULAR FONT, STYLE, SIZE, OR COLOR.
`
`SER NO. 85-220,267, FILED P.R. 1-18-201 1;AM. S.R. 3-2-2012.
`
`MA RIA-VICTORIA SUA REZ, EXAMINING ATTORNEY
`
`Reg. No. 4,133,304
`
`Registered Apr. 24, 2012
`
`Int. Cls.: 42 and 44
`
`SERVICE MARK
`
`SUPPLEMENTAL REGISTER
`
`
`
`Director ofllw United Slants Palem and ’I‘m(IcmuI'k ()fTu:::
`
`

`
`EXHIBIT D
`
`

`
`}'~z3w’
`‘
`
`Z;2i§1l;?.?-x‘
`
`Quizzes & Games
`
`Word of the Day
`
`Video
`
`S1lV‘«"«2’~t‘A",?l%
`
` i’.l'I” ,
`
`
`
`New Words
`
`My Favorites
`
`
`Now!
`Spanish Central v
`
` 3;;; <Cl?§l\lEEC>
`
`»E::?€??‘;‘}1' your
`well:
`€:€-Z*Z7€;¥§§E3t"siC‘3-
`
`
`neiwork
`
`
`Test Your Va , Lbixlaryr
`Take Dur10.Question Quiz
`
`angel rietwmk
`crossover networil
`
`
`
`Mons catitzzms
`
`H
`V
`
`_
`,
`360 Swmgg Account
`'
`&;:i*.w
`32% f<
`Net: m:vs3n~::siw's@ fr
`
`
`VaNW‘.(L8QilZ1lOi‘iO3f5UlC0m
`
`
`
`
`,,w*~‘*u,
`‘ '
`V
`
`“
`
`El“: fmiér
`
`3119’:-work
`
`Name That 'I‘hin;;;
`Take ourvisual vocabulary quiz
`Test ‘four Knowlarfige »
`True 02* Fzzlse?
`A quick quiz about stuff worth knowing
`Fake it Now »
`
`fl-éifiééf?
`
`: a system of lines, wires, etc, that are connected to each
`other
`I a system of computers and other devices (such as
`printers) that are connected to each other
`
`: a group of people or organizations that are closely
`connected and that work with each other
`
`H221 €}«afi:xil£1'>:':
`
`9:»? M §Wi1M&$£
`
`I
`
`
`a fabric or struclzure of cords or wires that cross at regular
`:
`intervals and are knotted or secured at the crossings
`
`
`
`Qfii
`
`_
`
`I
`
`
`:
`
`'
`,
`
`Hcaltlxlflzarx ‘
`‘ TTJFTS
`Mfidiwxa Pmfermd
`
`_
`
`
`i
`
`V
`H
`vw‘ l
`
`5594211 It
`The commonly misspelled words quiz
`Hm" H’ SW“ I”
`
`
`
`,
`_
`y
`mm M: Mom
`
`Big Woxxisa on Campus
`return (0 school
`Nerds that spike in iookups when students
`
`
`
`
`is a I,0wa.l;v "£‘ricI<," &
`"A ‘Else
`More-
`Favorite Qiioiations About Words. Vol.
`1
`
`
`
`
`
`
`g;m,y £j{)|$f}&[{{;1Efl
`
`‘
`
`I Get Out‘ Fwy;-': Aiyps
`" Voice Search, Favoriles,
`Word of ihe Day. and More
`lPl102‘iC5IlPZl(3 I Anrliuizl I More
`
`Join Us on 1-33 in Twittar
`Get the Word oftlie Day and More
`Eacebook liwltier
`
`
`
`a system of lines or channels resembling a network
`:
`a : an interconnected or interrelated chain, group, or system
`<a network‘ of hotels)
`
`: a system of computers, peripl1er‘als., terminals, and
`1)
`,
`A
`W
`databases connected by communications lrnes
`
`a : a group of radio or televésion stations linked by wire or
`
`radio retav
`b :
`a radio or television company tnac produces programs for
`broadcast over such a network
`
`a usually im‘ormaiiy interconnected group or association of
`5 :
`persons (as friends or professional colleagues)
`all See network defined for English-language learners »
`See nextworlz defined for kids »
`
`Rfizim :1 to r~a{.£W~:,>l~r,1~:
`
`'


`—
`—
`~
`—
`~
`r
`E §,mse;;::«.:«lzir é‘slr.7H'l.’£.?§~?.?<
`« He hoolced up his computer to the networlc
`
`'
`
`» The show is getting good ratings for the network
`
`iirearmm Wm oi’ %%éi1;l‘vfi.ffE§§‘«<
`
`
`1535
`
`
`
`
`
`
`
`
`mesh, riemng, ‘net
`
`l'€'l".'lY'l“,
`
`€3§§i£‘5‘fi~:51;’«g)i§¥rar
`
`§v’.2‘*§;<s§‘ni?
`
`lawram
`
`adware, flash, kludge, pnislwing, recursixm, rarsétcr
`
`1.~é.E1i{¥l‘ii?“4 wéila W’. 1Wi}n:34:
`
`‘
`arl;wr;>ri<., at work, Eaeariivrsrlc berserk: ‘oi Lfi<’1‘:IWv’0i'k,
`inridgework, brighrwork, brushwork, capcv/ork, casework,
`::ioci<woz'l<, <:oachwor‘l<1 d,,.
`:_'+} morz~:
`
`i11erwo1~i< me,
`
`: to Connect (computers) in a wayrhat-allows information
`and equipment to be shared
`
`I to talk with people whose jobs are similar to yours
`especially for business opportixnities or advice
`
`

`
`EXHIBIT E
`
`

`
`Ausmxlinn {3()V(’I“lml(‘lli'
`
`Dcplrrlnwm nl lmlustry
`
`rrra
`,
`l
`.sp,Qns9‘ra 1
`
`
`
`
`
`I C-Qnsurner’ guide to
`V clinical trials
`
`
`
`
`
`--» fiww
`'Tne13r;rrs.mnr=rs Héalrlr l‘~‘urrsm
`na\r2- rlevelrmszrf a facrslme:
`<“u_l‘}QlIt clinical mals.
`-,v—
`‘lforrsrxnmr ankle to Clmiral
`Trlals (l’i')l‘5,
`‘.l’(ll)KS%
`
`
`
`
`
`Hume, » ‘wit? xi rm. n . e.,
`
`Find a clinical trial website
`
`Clinical trial sites, clinical s, clinical trial resource organisations and
`clisease/condition~speclfic s"'upp0rt groups
`~
`(illnicnl rrlal site «- r'lzel‘lnt>,d as a l’lC.lll--CI(}lTll'l’ll‘3l'Cl8l entlty leg a lrosplral or research Institute) that (;Oll(.'llJ(Ll§ clmlcal trial researclr or r,lrltlr.>,r whose
`a clmlcal trial ls ccmrlucrcd.
`
`
`
`
`
`clolrrxrrd as armrganlstttron that l'Jf0\Ill,l(*,S rnfommtlnn, gtrldmlce, rtzscourclés or other SEl'VlC(l.S to the ptmllr.
`,S0lll'C(‘, urgarr ..ation
`. initial rial r
`related to umlrsrstancllng £3l'()éll{l(1l§I)8llllg an clrnlcal trial litfil-,‘al’(’ll.
`~ Disease/Ctmrlltl<m~3pe<:ll‘lt Stlppofl group tltrlluetl as an organlsatlon lllé1l,SLll.‘l{3(}({S partlcipatlon in clinical trial resraartlr associated with a
`s2:mcll‘rr.: Cli5€ElSl3. condition or set of rlisaases or conditions via advocacy, promotion or networlmg.
`
`Australian clinirral trials wetsslte external wellslte ellglbillty r‘equlrerrIen1‘s,
`Furtlrer mlormation on external webslres mclucled In the clinical malwelnsltes searclr.
`
`Search
`
`Dlseage orcczntlltlorrz
`<Any>
`
`or sort lily Organlsatlon name A--Z
`
`Keywords:
`01'
`
`
`5191115!
`
`ArB(:DEFCsH‘JKLMNC)PQR.S1_UV\NXYZ($hOWa.”)
`
`Addiction Neuroszcletntze Network Australia
`
`Aclrilttzlwrz l\3x2urosc,rerrlct=, hl2et'w<>rl< All$('l'zillél is at networl; of arlrlrction ¥l+‘,l.ll()$ClQllll$'[iS ézéllklbllsllétl to facllstare re;sea‘rcl*r collanoratlons
`
`
`
`Alzheimer’s Australia Research Limited
`
`.x\lz.lw,srnm’s Atrsmtlra Research l..lrr\§te,<3 movlrles lrllorrrralion, supnort, tmrrrsallllrg, tralnlng and é?£lllC<'ll'll3l'l. at: well as national prnllrrv and
`advocacy, for people wlth dementla.
`
`
`ANZAC Research lnstltute
`
`ANZAC Research Institute undertakes and collaborates in basic, clinical and epidemiological research, with a particular focus on ageing.
`
`
`
`Applied Science & Nutrition (ASN)
`Arlpllaérl fZ>rle.llc.e 6; Nutrltlon (ASND is a l3rlsl>ae1r:~llas,<ad mnmarlv that movlrles mnsultmg ser'vrt.e5 to thra nutr‘acel1:l<:a| and rmrlplemenrzrry
`rnedlt‘lm.= mtlrrstry, and (,()lldlll,‘l‘.s <:llnrt:al trials 10 assess the el‘l’et'ti of natural ll€al1‘lllJlOl.ll.l('lS.
`
`
`
`Arthritis Australia
`
`Arthritis Australia is a support and advocacy organrlsatlon for people with arthritis, and both funds researtll projects and provides details of
`current research and clinical trials,
`
`
`
`7 pip‘ ugars
`Aattlrtla
`
`.......s....=...,.
`uuuusuluu
`
`"l"l
`
`Asthma Foundation provides asthma inforrnatlon, etlucarlon, tralnlng and advocacy; prumotes asthma research; and provldes details on current
`research and trlals.
`
`
`
`

`
`EXHIBIT F
`
`

`
`’
`

`
`\V
`
`.64/_A
`
`./»
`
`/‘
`/
`
`-
`
`I-Zper‘ (mémb5rsh§p_E§ free} .
`Epemécu
`upcsntu ctfireniatxdfdxsner 7
`Ve'5ear:;hsCien1i*!:;_.
`‘
`—
`*
`
`.
`
`f _F.i(st rizsmgt
`
`‘
`
`guonimueg ~
`
`Aimady a member?
`855m in 1:; View Rabbfi hm ptaflle,
`
`V. P. Clinicaé Mfsxirs
`Clarisonir: ifiellevue, WA}
`F-‘l1.L).. ln?ecticLIs Dieeatselimmunekagy , Texas A&%‘~/I Univeiséty
`(Coliego Statics», TX)
`-1 M 3,, Béaiogyffiotanyfmycalogy, '1a:<as Siam Universéiy (San Mzzrcos.
`TX)
`B.f:‘.y E33cz1ogy1T»!rm-vasimw Piemts, University of 'I'rsxa5» ai Ausiin
`(Austin, TX)
`
`7'00? -2003
`195??-300%‘
`
`Prrtxgram Manager filswimrwationat Lab flevelopmem) Hi‘!
`Sr Sciemrst tar Scmlcaro Tqathbsush
`
`Ra his §».£a¥i<ig
`
`Robb Akridge, PI1.D.
`
`

`
`EXHIBIT G
`
`

`
`{HS establishes new network to perform clinical studies
`
`http://www.hhs.gov/news/press/20l4pres/O3/201403 l lb.html
`
`HHS.gov
`
`U.S. Department of Health & Human Services
`
`
`
`FOR IMMEDIATE RELEASE
`
`March 11, 2014
`
`HHS establishes new network tg Cal stud'es
`
`
`
`__,,...a.«»dfi"'-“"““"‘“’””
`
`ma
`
`Contact: HHS Press Office
`
`202~690—6343
`
`Network can prepare, conduct clinical studies for drugs to protect health in emergencies
`
`HHS today established a network of five clinical research Vowrggamnj_zati,ons that will design and
`conduct clinical studies"r’f§eded to develop medical countermem5§UF"€s
`— drugs, vaccines, and
`
`
`
`diagnostic tests that help protect health against bioterrorism, pandemic influenza, and other
`
`public health emergencies.
`
`The new clinical studies network will provide a full range of services required to plan, perform,
`
`monitor, and interpret clinical studies. The services include performing clinical studies that are
`
`required by the U.S. Food and Drug Administration for the approval of a product for human use,
`comparing the properties of multiple products, or evaluating the potency of products stored in
`
`U.S. government stockpiles.
`
`If needed, the network will also be able to supplement National Institute of Health capabilities
`by conducting clinical studies during public health emergencies such as a pandemic. This
`capability will enhance the nation's science preparedness by ensuring that clinical studies that
`address critical research questions for emergency response and recovery can be performed in a
`
`timely manner.
`
`“Recent disasters, such as Hurricane Sandy, the Deepwater Horizon oil spill, the 2009-H 1N1
`pandemic, underscored the importance of developing a capability to perform rigorous scientific
`
`studies in real time, potentially to shape the response to an unfolding crisis and to support
`recovery,” explained Robin Robinson, Ph.D., director of the Biomedical Advanced Research and
`Development Authority (BARDA). BARDA is part of the HHS Office of the Assistant Secretary for
`
`Preparedness and Response and will manage the clinical studies network.
`
`In an emergency, the BARDA clinical studies network may use local institutional review boards
`or the national Public Health Emergency Research Review Board, a central institutional review
`
`board administered by the National Institutes of Health to review multi—site research studies on
`
`health problems arising in the context of a public health emergency. Both types of boards assure
`
`that appropriate steps are taken to protect the rights and welfare of people participating as
`_ .9.
`ELL
`(fl
`n tne research.
`subL.-
`
`The clinical studies network will support BARDA=funded medical countermeasure developers and
`
`conduct clinical studies on behalf of BARDA. The activities of BARDA’s clinical studies network
`
`lof3
`
`8/27/2014 1:50 PM
`
`

`
`'-[HS establishes new network to perform clinical studies
`
`http://www.hhs.gov/news/press/2014pres/03/20140311b.html
`
`will be coordinated with those of HHS interagency and industry partners, including the National
`
`Institute of Allergy and Infectious Diseases (NIAID).
`
`ASPR awarded contracts to five U.S. companies that will make up the network's clinical studies.
`
`Today's contracts are with EMMES Corporation of Rockville, Md.; PPD Development LLC of
`
`Wilmington, N.C.; Technical Resources International Inc. of Bethesda, Md.; Clinical Research
`
`Management, Inc. of Hinckley, Ohio, and Rho Federal Systems Division Inc. of Chapel Hill, N.C.
`
`M Each contract includes a minimum guarantee of $400,000 over the initial two years for access to
`the clinical research organization's services. Each contract can be extended for up to a total of
`
`five years and a maximum of a $100 million. Clinical studies will be performed through the
`
`network based on proposals provided by the network members in response to specific BARDA
`
`requests.
`
`The new clinical studies network expands the core service assistance programs through BARDA
`
`to aid medical countermeasure development. In addition to the clinical studies network, BARDA
`
`oversees a nonclinical development network, Centers of Innovation in Advanced Development
`
`and Manufacturing (CIADM§), and a fill finish manufacturing network.
`
`The nonclinical development network supports preclinical testing of medical countermeasures
`
`while the CIADMS provide an array of manufacturing services and influenza vaccine surge
`
`manufacturing capacity. The fill finish manufacturing network covers the final steps in the
`
`vaccine manufacturing process and supplements the filling capacity of current influenza vaccine
`manufacturers.
`
`BARDA provides a comprehensive integrated portfolio approach to the advanced research and
`
`development, innovation, acquisition, and manufacturing of vaccines, drugs, therapeutics,
`
`diagnostic tools, and non—pharmaceutica| products for public health emergency threats. These
`
`threats include chemical, biological, radiological, and nuclear (CBRN) agents, pandemic
`
`influenza, and emerging infectious diseases.
`
`ASPR leads HHS in preparing the nation to respond to and recover from adverse health effects of
`I
`um
`hstand adversity, strengthening health and
`
`emergencies, supporting communities’ ability to wit
`
`response systems, and enhancing national health security. To learn more about ASPR and
`
`preparedness, response and recovery from the health impacts of disasters, visit the HHS public
`
`health and medical emergency website, www.phe.gov.
`
`HHS is the principal federal agency for protecting the health of all Americans and providing
`
`essential human services, especially for those who are least able to help themselves. To learn
`
`more about HHS, visit www.hhs.gov.
`
`###
`
`Note: All HHS press releases, fact sheets and other news materials are available at
`
`’.of3
`
`8/27/2014 1:50 PM
`
`

`
`Jung-MAP Launches: First Precision Medicine Trial From National C...
`
`http://www.cancer.gov/newscenter/newsfromnci/2014/LungMAPlaunch
`
`News
`
`Contact the NCI Office of Media Relations | RSS Feed
`
`In English
`Posted: 06/16/2014
`
`NCI Press Release
`
`Lung—MAP Launches: First Precision Medicine Trial From
`National Clinical Trials Network
`
`
`
`A abQLat flg .
`WWW“
`.
`.
`..-. cr nstitute V,
`.
` rt e Natiopal
`Institutes of Health, SWOCG Cancer Research, Friends of Cancer Research, the Foundation_fiQ_;_the
`National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentbe_g_h,,,Efi_ger,
`,..,....,._............,v
`'5 AstraZeneca, and AstraZeneca’s global biologics R&D arm, Medlmmune), and Foundati0nW1\”/lflegoicine
`today announced the initiation of the Lung Cancer Master l’_f5to"dolm(Lung—MAP) trial.
`......—-we.-.....,._............._......««
`...u.a1_s...¢...M....=.
`
`
`
`I Lung—MAP is a multi—drug, mu1ti—arm, biomarl<er—driven clinical trial for patients with advanced
`squamous cell lung cancer. Squamous cell carcinoma represents about a quarter of all lung cancer
`diagnoses, but there are currently few treatment options beyond surgery for the disease. The trial will use
`genomic profiling to match patients to one of several different investigational treatments that are
`designed to target the genomic alterations found to be driving the growth of their cancer. This innovative
`approach to clinical testing should both improve access to promising drugs for patients and ease the
`significant recruitment and infrastructure burdens on researchers involved in traditional clinical trials.
`
`
`
`w__d______.........._...................__
` -mu
`—.........._l.__m...&w.
`“This diverse, collaborative approach, with s mdmg lun cancer advocac 0rg§.I.1,LZaIions,
` mWWmWfli.
`,
`t
`helps to ensure that he needs of patients, clinicians, developers, and regulators are all considered in the
`desi
`n
`of the trial,” said Dr. Ellen Sigal, Chair & Founder of Friends of Cancer Research.
`rm 2 d operatm
`
`The trial will initially test five experimental drugs——four targeted therapies and an anti—PD—L1
`imrnunotherapy. It is anticipated that between 500 and 1000 patients will be screened per year for over
`200 cancer—related genes for genomic alterations. The results of this test will be used to assign each
`patient to the trial arm that is best matched to their tumor’s genomic profile.
`
`
`dri tret .,
`@ “ ung—MAP re resentsthefirstofseveral plannedlarge, gen0micay—
`con am1mangmNmN), sid Jeff Abrams, M.D.,
`Xssbciate Director of NCI’s Cancer Therapy Evaluation Program. “The restructuring and consolidation of
`NCI’s large trial treatment program, resulting in the formation of the NCI“N, is quite timely, as it now can
`offer an ideal platform for bringing the benefits of more precise molecular diagnostics to cancer patients
`
`
`
`in communities large and small.”
`
`"Squamous cell lung cancer, like many other neoplasms, is increasingly recognized as consisting of a
`of relatively rare genomic subsets, each of which may require treatment with a different targeted drug,
`
`-st
`
`1 of2
`
`8/27/20l4 1:50 PM
`
`

`
`iung—MAP Launches: First Precision Medicine Trial From National C...
`
`http://wwwcancer. gov/newscenter/newsfromnci/2014/LungMAP1aunch
`
`said Dr. Charles Blanke, Chair of SWOG Cancer Research. “The Lung—MAP S1400 trial models a way to
`efficiently study a large number of these rare squamous cell subsets under one master protocol."
`
`Lung—MAP aims to establish a model of clinical testing that more effici

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket